Member Info for nursesteve

Thanks Wibblewobble increasing their exposure 🤔 very positive. This alongside other recent notification of notifiable holdings bode well for the future direction of the SP. GLA 👍

The resulting situation seems to be an increase in voting rights from 1.9 to 2.9 %? Indicating confidence in the company but I’m not sure about the CFD Spread bet information ? 🤔

Does the RNS mean they’ve altered the number of voting rights that they hold or simply reduced a long spread bet slightly?

IMHO it could and looking at it’s 52week range it could easily multi bag from its present SP. Happy to hold and see. GL

DugWalker - the RNS includes a statement from Robin Clark, MEDICAL Director for Bupa Insurance, who said: "We're pleased to partner with Oxford BioDynamics to cover the advanced EpiSwitch PSE test. The PSE provides a more accurate path to diagnosing prostate cancer, where getting an early diagnosis can make the disease nearly completely survivable. Offering the PSE and CiRT tests reflects our commitment to leverage the most advanced precision medicine testing to provide doctors with the tools they need to make informed decisions." So Yes I do expect their doctors to use these tests.

BUPA recognises the value of these tests. Likewise professional investment group Sankofa Strategic Equity Fund Limited (who took a 6% plus stake in early Feb 2025) also recognise the potential of the tests and are looking for a return on their investment from OBD. Iain Ross has experience In the turnaround of several biotech companies and he wouldn’t have taken up the role of Executive Chairman if he didn’t believe he could change OBD’s outlook.

Is currently leading a review expected to be published around the time of the AGM of the groups current operations. Any potential cost savings from that review have not been included in the company’s recently published AR (not even in the upside forecast).

Seems to be a binary gamble but I’m happy to be taking the punt. Should know soon if it is going to pay off. GLALTH’s

So they have data to present and they’re focused on American investors? 🤔 listing getting much more likely ?

Sunak worked as an analyst for the investment bank Goldman Sachs between 2001 and 2004. He then worked for hedge fund management firm The Children's Investment Fund Management (TCI), becoming a partner in September 2006.

IMHO the market is confusing data from poor home PSA tests with the PSE test which improves testing results to 94% accuracy. The EpiSwitch Prostate Screening test is not an at home test - usually the tests are done by your GP although occasionally patients might request their blood sample is taken at home by a nurse but the test analysis is all done in a lab. see https://www.google.com/search?q=EpiSwitch+Prostate+Screening+test&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari

Slacker that’s their guidance and they’ve proven it improves accuracy to 94%!

674,037 more

Proven to be unreliable PSA tests vs EpiSwitch 94% accurate PSE test, should equal increased demand, sales, profit and SP! 🤞

GLALTH’s

Interesting the price they paid is higher than the current SP . Also of interest is a bbc article today “Warning over rapid at-home prostate tests” might just see un uptake in demand for the Episwitch test?

But also better results to follow

I’m expecting good results Friday!

Or the dampening of placement shares being flipped?

What will move the share price onto a sustainable upward trajectory ? 🤔

Is the lacklustre performance to today’s RNS just a reflection of the adage to ‘sell the news and buy the rumour’?

Noticed them yesterday as well 🧐

What’s with all these frequent trades? Are they trying to get the price down to below the placing price? 🤔